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differential susceptibility to cancer and, undoubtedly,
to variable efficacy and toxicity of pharmacological-
based therapeutics. Many of the specific molecular
processes involved in human tumorigenesis have been
elucidated and accurately modeled in mice. However,
the current models used for drug testing do not accu-
rately predict how new treatments will fare in clinical
trials. More sophisticated models that treat cancer as a
complex disease present within heterogenous patient
populations will provide better predictive power to
identify patients that may benefit from specific thera-
pies or that may develop potential drug-induced toxi-
cities.*Corresponding author: D.W. Threadgill (dwt@med.unc.edu)
a These authors contributed equally to the development of this review.
1740-6757  2007 Elsevier Ltd.  DOI: 10.1016/j.ddOpen access under CC BY-NC-ND license.Section Editor:
Kevin Mills – The Jackson Laboratory, Bar Harbor,
ME 04609, USAIntroductionIt is increasingly clear that pharmaceutical-based cancer
therapies provide variable and often unpredictable patterns
of efficacy among patients. Additionally, unpredicted or off-
target toxicities within patient populations are a growing
concern that has been highlighted in the lay press over the
past several years. While animal models, especially mice,
have been used extensively by the pharmaceutical industryfor mechanistic studies and safety testing, the commonly
used approaches and mouse models are not appropriate to
address many of the complex genetic and environmental
contributions underlying varying therapeutic effects and/or
toxicities in patient populations. Herein we compare current
models and suggest new approaches to more accurately
model heterogenous patient populations.
In vitro model systems
Cell-based platforms
Cell-based screens are an efficient and cost effective platform
to identify potential therapeutic targets, to investigate
mechanisms of action and to assess cellular toxicity in early
stages of drug discovery. While these screening approaches
may be effective in identifying potential therapeutic lead
compounds, their predictive value for the clinic is limited.
Readily available cancer cell lines have been maintained in
culture for many generations of passage and usually have
acquired many unknown genetic alterations. Uncharacter-
ized mutations may affect the validity of conclusions and
long-term reproducibility. It is also not uncommon for cell
lines to be cross contaminatedwith other cell lines aftermanymod.2007.06.004 83
Drug Discovery Today: Disease Models | Cancer Vol. 4, No. 2 2008years of repeated culturing. The German Cell Bank (DSMZ)
has estimated that 29% of all human-tumor cell line submis-
sions contain cross contamination [1]. While certain drugs
may have positive results in cell line screens many other
physiological factors may affect the overall performance of
lead compounds including the surrounding microenviron-
ment of cancers in vivo and the underlying genetic hetero-
geneity of the patient populations that may affect efficacy,
metabolism, as well as susceptibility to toxicity. Strategies
using panels of cell lines have been developed to overcome
some of these limitations, such as the National Cancer Insti-
tute’s panel of 60 cancer cell lines (http://dtp.nci.nih.gov)
that have been used to test thousands of chemicals. Another
strategy is to combine in vitro cell-based platforms with in vivo
growth assays like xenograft models.
Xenografts: an in vivo petri dish
The current gold standard for testing the efficacy of cancer
pharmaceutical therapeutics in vivo is the xenograft mouse
model. In this model human tumors are subcutaneously
implanted into immunocompromised mice and drugs are
administered either locally or systemically. Following treat-
ment, tumors are assessed for changes in size, vasculature
metastasis to distant sites, among other measures. Although
xenografts may be efficient in detecting therapy-induced
changes to specific cancer cell growth characteristics, the pre-
dictive power of this model has been modest at best. Previous
studieshave shown that only 3.8%ofpatients in Phase I cancer
drug trials show a significant clinical response [2]. Most, if not
all, drugs that failed in humans worked on subcutaneous
xenograft tumors in mice. It is apparent that there is a large
discrepancy in the relationship between artificially implanted
xenograft models and in vivo arising cancers.
While these models may be effective for determining
whether pharmaceutical drugs hit their appropriate targets
and cause changes in specific cancer cell characteristics, they
have significant shortcomings when compared with sponta-
neously occurring tumors in humans. One of the main issues
is the lack of an intact immune system in xenograft recipi-
ents, which is a well-established component of cancers that
can have both growth promoting and growth inhibiting
properties. Another issue is that these implanted tumors
are grown in a subcutaneous environment lacking a host
stromal compartment that evolved with the cancer. Differ-
ences in the tumor microenvironment compared with the
normal tissue of origin may have a profound impact on
growth and survival of cancer cells since this artificial envir-
onment has different cellular compositions and vasculature
processes. Orthotopic implantation, injecting the human
tumors into the corresponding mouse organ tissue, may
resolve some of these issues, but this route of implantation
is not practical because of extensive procedure time and
the inability to accurately mimic the location and growth84 www.drugdiscoverytoday.comenvironment of the human tumors from which the cells
were derived.
Both of the immunocompromisedmice commonly used for
xenografts, severe combined immunodeficient mice (SCID)
and Nude mice, are usually maintained on a single or mixed
genetic background that eliminates the ability to detect host
specific genetic modifiers that may contribute to varying
pharmacological and toxicological effects in humans. Finally,
xenograftmodel platforms rarely incorporate important envir-
onmental factors, such as diet, in assessing the efficacy and
toxicity of pharmaceuticals. With the current knowledge on
the role of diet in cancer, drug–food interactions, and differ-
ential effects of diet across mouse strains and humans, the
human diet, which is substantially different than normal
mouse chow, is likely to contribute to reduced predictive
power of mouse models as described below.
The simplistic xenograft model system is generally
regarded as not being predictive for therapeutic efficacy
and has lead to significant criticisms of the value of mouse
models for drug discovery and testing [3], despite the fact that
xenografts are not mouse models of human cancer but are
primarily a complex in vivo cell culture system. These models
may even be responsible for prematurely canceling the devel-
opment of candidate drugs thatmayhave efficacy in humans,
but data are not available for drug leads not pursued based
upon failure in xenograft studies. Although the vast majority
of cancer pharmaceutical companies use these models, the
low success of subsequently developed drugs in human clin-
ical trials indicates that more accurate mouse cancer models
must be utilized to specifically model the complexity of
tumorigenesis as it occurs in humans.
In vivo model systems
Advanced molecular mouse models of cancer
Transgenic, knockout, and knockinmousemodels with spon-
taneously arising tumors have been developed that demon-
strate many of the molecular and histopathological changes
associated with human cancer progression from initiation
through metastasis (see the National Cancer Institute’s
Mouse Models of Human Cancer Consortium (MMHCC)
web site: http://emice.nci.nih.gov). Although these models
have been used extensively in basic research investigations
into the mechanisms of tumorigenesis, their use in pharma-
ceutical preclinical testing has been limited. With the short-
comings of the xenograft models in cancer drug development
becoming more widely acknowledged, it is appropriate to
entertain the use ofmore complex but realistic mousemodels
of human cancer for preclinical testing. Unlike xenograft
models, engineered mouse models retain an intact immune
system and a host-derived tumor microenvironment that
accurately models that is present in human cancers.
The first transgenic mouse models of human cancer were
generated in the 1980s when MYC overexpression in the
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adenocarcinoma [4] and mutant KRAS expression led to
the oncogenic transformation of pancreatic cells [5]. These
models demonstrated that expression of human oncogenes
in the mouse could successfully initiate tumor development.
Subsequently it was shown that knockouts of tumor suppres-
sors such as Trp53 or Rb would induce a spectrum of tumors
including lymphomas, sarcomas and pituitary adenomas
[6–8]. Unfortunately, the concept of engineering mice to
develop cancer and their use for preclinical trials were
patented. DuPont licensed the patented ‘OncoMouse’ in
1988, preventing the production and exchange of these
models without a license. Many have argued that the cost
and restrictions imposed by these licenses have hindered the
adoption of more accurate mouse models by the pharmaceu-
tical industry for preclinical therapeutic development and
delayed development of more intelligently tested drugs,
which has increased the cost of drug development despite
the lower cost of the xenograft models compared with more
clinically accurate engineered and spontaneously arising
mouse cancer models [9,10].
Since the first generation mouse models of human cancer
were developed, numerous and ever more accurate models
have become available for most cancers including brain,
breast, colon, lung and prostate cancers (Table 1). Models
have been designed and built to display varying stages of
tumorigenesis ranging from initiation through metastatic
disease making them useful for evaluating therapies against
particular stages of cancer progression. Cancer is a disease
with multiple mutations and epigenetic alterations usually
involving activation of oncogenes (Myc, Kras, among others)
and loss of tumor suppressor genes (Trp53, Rb, among others).
While single gene transgenic and knockout models are suffi-
cient to induce tumorigenic events in the mice, more com-
plex models that recapitulate the multiple genetic events
occurring in human cancers have been developed. Illustrative
of the remarkable similarity between the latest generation of
mouse models and human cancer is the development of a
mouse pancreatic cancer model that progresses from initia-
tion to invasive, metastatic disease that was engineered by
introducing an activated Kras gene with pancreas-specific
expression along with loss of the tumor suppressor Cdkn2a
[11]. These two mutations occur in almost all cases of human
pancreatic adenocarcinomas, yet only mice expressing Kras
display signs of early stage pancreatic tumor growth while
mice lacking Cdkn2a have no neoplastic lesions in the pan-
creas. This mouse model should have specific utility in pre-
clinical testing for pancreatic cancer drug development since
it recapitulates both the molecular and histopathological
changes observed in human pancreatic cancer. Greater use
of genetically engineered immunocompetent mice to model
the order and spectrum of mutations observed in humans
can only improve the predictive value of mouse models forthe discovery of cancer therapeutics and will lead to lower
drug development costs because of more informed evalua-
tions in realistic models before incurring the expense of
clinical trials.
Genetic modifiers
Pharmacology studies have traditionally used mice from
inbred or undefined genetic backgrounds for drug discovery
and toxicity testing. However, studies based solely on results
obtained using one inbred strain or model do not support
clinically important insights or the full appreciation of the
response spectrum likely to be encountered in the clinic. This
insight can only be achieved by investigating the genetic
context of efficacy and toxicity. Different inbred mouse
strains have varying susceptibility to spontaneous or chemi-
cally induced tumor formation [12,13], and specific modifier
loci have been identified in mice that lead to susceptibility to
specific cancers [14,15] and varying toxicological responses
[16]. For example, the Pas1 locus has been identified to
predispose mice to lung tumor development [17]. Depending
on genetic background, the activity of the same allele may
even switch from resistance to susceptibility to cancer [18].
These differences demonstrate the importance of genetic
background in cancer development, and use of this informa-
tion will provide a better understanding of how humans
differ in their response to pharmaceutical therapies and/or
susceptibility to drug-induced toxicities. A ‘one-size-fits all’
mouse model approach will not be sufficient to provide the
best preclinical predictive power.
Genetic background can dramatically modify the effect of
engineered mutations on tumor growth and survival and by
extension, on the efficacy and toxicity of preclinical thera-
peutic trials. Patients developing cancers with specific genetic
mutations often have different survival rates and respond to
therapy with varying degrees of success, presumably as a
result of unidentified genetic modifiers. Although requiring
substantial changes from the status quo, incorporating
knowledge of genetic modifiers into preclinical tests will
improve extrapolation of results to patients and identifica-
tion of patient populations best matched to particular thera-
pies, leading to more accurate and cost-effective translations
to the clinic.
Humans are not inbred nor genetically homogeneous, so it
is over-simplistic to assume that a single inbred mouse model
will be sufficiently representative of the genetic heterogeneity
present in patient populations. By identifying and under-
standing modifier loci in mice that alter therapeutic response
or susceptibility to toxicity, polymorphisms in orthologous
genetic loci in patients enrolled in clinical trials can be
considered to increase the probability of successful transla-
tion to the clinic. Inevitably, future cancer therapies will be
personalized to the patient’s spectrum of tumor mutations
and their constitutional genetic makeup.www.drugdiscoverytoday.com 85
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Table 1. Mouse models of human cancer
Cancer site Mouse model Refs
Brain
Medulloblastoma Ptc+/; p53, GFAP-Cre; Rbloxp/loxp [30]
Astrocytoma GFAP-v-src, GFAP-HRas [30]
Glioblastoma NPcis [31]
Breast
Low-grade mammary intraepithelial neoplasia MMTV-LTR/int3, MT/HGF [32]
High-grade mammary intraepithelial neoplasia C(3)1/SV40 tag, WAP/TGFa [32]
Papillary carcinoma MMTV-LTR/cyclin D1, MMTV-PyV-mt [32]
Human ductal carcinoma in situ (DCIS) MMTV-c-erb-B2 [32]
Colon
Adenoma Apcmin/+; ApcD716, Apc1638N/+ [33]
Adenocarcinoma Mlh1/; Apc1638N/+, Msh6/; Apc1638N/+, Msh3/; Apc1638N/+ [33]
Mucinous carcinoma Tgfb/; Rag2/ [33]
Lung
Bronchiolar neuroendocrine cell hyperplasia Rb+/; p53/ [34]
Adenocarcinoma Tg(Sp-C-LTag), Tg(CC10-Tag) [34]
Non-small-cell lung carcinoma K-rasLSL; p53, CC10-hASH1 [34,35]
Prostate
Low-grade prostatic intraepithelial neoplasia (LGPIN) PB-Ras, Nkx3.1/ [36]
High-grade intraepithelial neoplasia (HGPIN) ARR2PB-Skp2 [36]
Invasive carcinoma LPB-SV40 Tag (Lady model) [36]
Metastasis Pb-Cre4; PTENloxp/loxp, LPB-Tag; ARR2PB-hepsin, TRAMP model [36]Diet and nutrition
In addition to genetic predisposition, environmental factors
like diet can have a major impact on cancer risk and response
to therapy. It is becoming increasingly apparent that knowl-
edge about gene-environment interactions will be important
for improving cancer prevention and treatment. According to
the American Cancer Society an estimated one-third of all
cancer deaths in the United States are related to lifestyle, such
as diet and physical activity (http://www.cancer.org). The
interaction between environment and genetic susceptibility
and their influence on cancer deaths also varies among cancer
type; environment has the greatest impact on cervical, lung
and oesphageal cancers while leukemia and colorectal can-
cers are more heavily influenced by a combination of genetic
susceptibility and environmental factors [19]. The role of diet
in particular has been examined extensively in animal studies
and human epidemiological and clinical trials.
The ‘Western-style’ diet consumed in North America and
Europe that has high levels of fat and low levels of vitamin D
and calcium has been modeled in mouse experiments. Main-
tenance of mice on this diet induces hyperproliferation in
pancreatic, prostate, mammary and intestinal epithelial cells
of wild-type C57BL/6 mice [20,21]. Further modifications of
the diet to include decreased levels of folate and other nutri-
ents essential for DNA methylation induce intestinal adeno-
mas and carcinomas in wild-type mice [22]. Combining a
Western diet with an inactivation of Cdkn1b, coding for a key
cell cycle regulator, results in an additive effect on intestinal
tumorigenesis compared with Western diet or Cdkn1bmuta-86 www.drugdiscoverytoday.comtions alone [23]. Analogous effects on therapeutic response or
susceptibility to drug-induced toxicity are predicted to occur
despite the dearth of studies in this area.
Another factor not usually considered is the more than
50% of adults taking at least one type of dietary supplement.
Recent studies on the molecular mechanisms underlying the
effects of specific nutrients are being revealed and found to
intersect with many drug-target pathways known to be
involved in cancer [24–26]. In addition, individuals vary in
their ability to metabolize specific nutrients, and this differ-
ence has been correlated with cancer risk [27–29].
With the development and use of more targeted therapies
and with the increasing knowledge of how diet impacts the
same pathways, consideration should be given on how diet
and nutrients interact with cancer therapies. Results from
clinical trials have revealed that efficacy and toxicity of
chemotherapeutics is individualized with few preclinical
studies being predictive for these effects. Better designed
preclinical studies utilizing more than one mouse model,
genetic background and base diet have the power to account
for these variable circumstances, further improving the trans-
lational potential of mouse models by improving the pre-
dictive power and lowering the total cost of drug
development.
Improving model translation to humans
Mouse models have been used extensively to determine
the underlying causes of many human diseases long before
the genetic similarities between humans and mice were
Vol. 4, No. 2 2008 Drug Discovery Today: Disease Models | Cancer
Table 2. Comparison of models for preclinical testingappreciated. Their small size, relative affordability, short
gestational times and similarity to human organ systems
have made the mouse a convenient model to study human
disease. With the completion of the mouse and human
genome sequence, it is now known that 40% of the human
and mouse genomes can be directly aligned and greater than
80% of human genes have a direct orthologous gene in the
mouse genome [26]. These data suggest that the mouse can
not only serve as a physiological model for preclinical drug
testing but can also be utilized as a model for studying the
underlying genetic variation among individuals that modu-
lates therapeutic response.
It is evident that traditional methods of pharmaceutical
research are not adequate for painting the full picture of how
a population of patients will respond to new therapeutics
(Table 2). The use of homogenous ‘in vitro’ mousemodels has
proven to be economically inefficient when the total cost of
drug development from target identification to clinical trial
is considered. This is evident in the fact that a large number
of drugs reaching clinical trials never achieve approval by
the Food and Drug Administration (FDA). As the identifica-
tion of potentially new pharmaceuticals increases, it is
essential that parallel improvements be made in the use
of preclinicalmodels that accurately recapitulate the natural
development and progression of human cancers. Similarly,
models that incorporate host genetic variability and envir-
onmental conditions observed in clinical trials will improvethe efficiencies and reduce the costs associated with drug
development.
Conclusions
The sequencing of the human and model organism genomes
is beginning to have a beneficial impact on the progress of
drug discovery. An individual’s genetic background and
environment has the potential to significantly alter his/her
response to therapy or susceptibility to toxicity. As the gen-
ome era continues to transform our understanding of the
mechanisms behind human disease and response, the field of
cancer therapeutics must incorporate new insights based
upon models that accurately recapitulate the genetics and
environmental circumstances of human cancers if the success
of drug development is to improve.
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